About us

Corolabs develops unique aerosol generation technologies for soft-mist-inhalers coupled with specific medications for pulmonary drug delivery. Our unique technologies are geared towards providing simple, robust, user-friendly and disposable devices that generate soft-mist aerosol with low droplet size (below 1 microns) and high fine particle fraction (FPF).

Corolabs' technology is based on a scientific discovery in the fields of fluid dynamics and the interaction of airflows with thin liquid film


Livnat Ben Zur, CEO brings 20 years of experience in the medical device and combination products sectors, in the United States and in Israel. She brings high level management skills of medical device companies, leadership skills with a unique combination of business, fund raising, regulatory, clinical and management capabilities, successful strategic planning and execution capabilities for early stage medical device companies. 

Prior to joining Corolabs, Livnat was the General Manager & EVP of Regentis Biomaterials, and prior to that was VP Business Development & Director of Women’s Health Program at Galil Medical. Before that Ms. Livnat served as a Director of Marketing of Medinol, and prior to that as the Head of Medical Technology business unit at Datamonitor.  She holds a MBA in marketing and International Business and Bachelor of Sciences in Biology from Tel Aviv University

Asaf Weinberger, Chairman is the founder and CEO of Omega Life Science (OLS), a medical device company specializing in inhalation technologies. Asaf initiated the establishment of Corolabs. Previously, Asaf served as an officer engineer in the technological unit of the Israeli Defense Force for ten years. Following his military service, he was appointed as a representative of Israel Aircraft Industries in Southeast Asia. Asaf holds two degrees with distinction, an MBA and a B.Sc. in Mechanical Engineering, from the Technion, Israel Institute of Technology.

Dr. Miron Hazani, CTO has held senior R&D positions in leading companies in  the fields of microelectronics and nanotechnology.  Miron holds a Ph.D. in Biochemistry from Tel Aviv University, and conducted post-doctoral research  in chemical physics and nanotechnology at the  Weizmann Institute of Science, Israel.  Miron has invented all the technologies owned by Omega Life Science and its subsidiaries, including 4 aerosolization platforms and several formulations.  Miron developed the Laboratory Demonstrator and the Investigational Device.

Dr. Matan Dishon, VP of R&D brings a vast experience in both industrial and academic environments, dealing with medical devices, nano-science, biophysics, biochemistry and more.  Prior to joining Corolabs, Matan was CEO and Founder of SensEyez, a retinal imaging company.  He also served as CTO of O2Cure,  nanotechnology-based medical device developing a novel biomimetic, microfluidic based, gas-exchanger membrane for blood-oxygenators and artificial lungs and served as Chief Physicist at Palti Group, cluster of biomedical and medical device start-ups.  Matan holds a Ph.D. degree in Physics from the Technion Institute of Technology and taught there as an Assistant Professor.

Dr. Anthony Brehm, MD, Chief Medical Officer is an accomplished physician with US board-certified specialization in Pulmonary Medicine, Critical Care and Internal Medicine. Anthony has treated COVID-19 patients in the US. Prior to that, Anthony held medical positions including Director of the Stony Brook Center for Interstitial Lung Disease, Assistant Professor of Medicine in Stony Brook University, NY, Pulmonary and Critical Care Fellowship in St Luke’s-Roosevelt Hospital, NY and Albert Einstein Medical Center, Philadelphia. Anthony studied medicine at the University of the Witwatersrand Faculty of Health Sciences, JHB South Africa.

Prof. Tamas Bartfai is one of the world’s top scientists in the fields of biochemistry, pharmacology and neuroscience.  He has been involved at almost all large pharmaceutical companies, including Astra, Roche, Novartis and Pfizer, and co-launched several biotech companies. Prof. Bartfai has consulted on, directed or co-directed the development of at least eight approved drugs. Five of these were "first-in-class" drugs, including: zimelidine, alaproclate, omeprazol/Losec-Prilose, Tasmar-tolcapone, flunitrazepam and gilenya-fingolimod. He has also consulted for Saab, Siemens, and Nestlé. His awards include the Eötvös Medal, Svedberg Prize for biochemistry, the Hilda & Alfred Eriksson Prize by The Royal Swedish Academy of Sciences and also the Ellison Medical Foundation Senior Scholar Award.


Prof. Ori Rogowski MD, Head of the Scientific Board is one of Israel’s most eminent physicians, currently heading both (a) Internal Medicine “gimel” department in Ichilov hospital and (b) Corona department in Ichilov hospital.  Prof. Rogowski has been featured in television channel 13 news on 4/7/2020 as having successfully administered Dexamethasone and thus saving Corona patients in critical condition during the first wave, even before Dexamethasone was proven effective in a clinical trial by Oxford University.   Prof. Rogowski has been very supportive of Corolabs’ technology and value proposition and among other activities for the company he is leading the choice of drugs to be delivered using the Corolabs technology.